Alterations of molecular and behavioral responses to cocaine by selective inhibition of Elk-1 phosphorylation

Antoine Besnard1, Nicolas Bouveyron, Vincent Kappes

  • 1Inserm, Unité Mixte de Recherche en Santé 952, F-75005 Paris, France.

Insights

Elk-1 phosphorylation, downstream of ERK signaling, is critical for cocaine

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Extracellular signal-regulated kinase (ERK) pathway activation in the striatum drives cocaine-induced adaptations.
  • ERK influences mitogen and stress-activated protein kinase 1 (MSK-1) and Elk-1 phosphorylation, impacting gene regulation and neuronal changes.
  • Previous studies characterized msk-1 knock-out mice; this study investigates the role of Elk-1 phosphorylation.

Purpose of the Study:

  • To determine the role of Elk-1 phosphorylation in cocaine's molecular, morphological, and behavioral effects.
  • To investigate whether inhibiting Elk-1 phosphorylation affects cocaine-induced neuronal plasticity and addiction-related behaviors.

Main Methods:

  • Utilized a cell-penetrating peptide (TAT-DEF-Elk-1 or TDE) to inhibit ERK-mediated Elk-1 phosphorylation in vivo.
  • Administered TDE before cocaine exposure in mice.
  • Conducted immunocytochemical, molecular, morphological, and behavioral analyses.

Main Results:

  • TDE successfully inhibited cocaine-induced Elk-1 and histone H3 (Ser10) phosphorylation without affecting ERK or MSK-1.
  • TDE altered the regulation of cocaine-responsive genes with serum response elements (SREs), including c-fos and ΔFosB.
  • TDE reversed cocaine-induced increases in dendritic spine density and delayed psychomotor sensitization and conditioned place preference.

Conclusions:

  • Elk-1 phosphorylation is a key molecular event downstream of ERK signaling in cocaine's long-term effects.
  • Targeting Elk-1 phosphorylation offers a potential strategy for mitigating cocaine-induced adaptations and addiction.

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...